Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorDziadziuszko, R.
dc.contributor.authorPeters, S.
dc.contributor.authorGadgeel, S. M.
dc.contributor.authorMathisen, M. S.
dc.contributor.authorShagan, S. M.
dc.contributor.authorFelip, E.
dc.contributor.authorMorabito, A.
dc.contributor.authorCheema, P.
dc.contributor.authorCobo Dols, M.
dc.contributor.authorAndric, Z.
dc.contributor.authorBarrios, C. H.
dc.contributor.authorYamaguchi, M.
dc.contributor.authorDansin, E.
dc.contributor.authorDanchaivijitr, P.
dc.contributor.authorJohnson, M.
dc.contributor.authorNovello, S.
dc.contributor.authorGandara, D. R.
dc.contributor.authorSchleifman, E.
dc.contributor.authorWang, J.
dc.contributor.authorMok, T. S. K.
dc.contributor.authoraffiliation[Dziadziuszko, R.] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland
dc.contributor.authoraffiliation[Peters, S.] Lausanne Univ, Ctr Hosp Univ Vaudois, Oncol, Lausanne, Switzerland
dc.contributor.authoraffiliation[Gadgeel, S. M.] Henry Ford Hlth Syst, Internal Med, Henry Ford Canc Inst, Detroit, MI USA
dc.contributor.authoraffiliation[Mathisen, M. S.] Genentech Inc, Prod Dev Oncol, San Francisco, CA USA
dc.contributor.authoraffiliation[Shagan, S. M.] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA
dc.contributor.authoraffiliation[Schleifman, E.] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA USA
dc.contributor.authoraffiliation[Felip, E.] Hosp Univ Vall Hebron, Lung Canc Unit, Med Oncol Serv, Barcelona, Spain
dc.contributor.authoraffiliation[Morabito, A.] IRCCS, Thorac, Ist Nazl Tumori Fdn G Pascale, Naples, Italy
dc.contributor.authoraffiliation[Cheema, P.] Univ Toronto, William Osler Hlth Syst, Med Oncol, Toronto, ON, Canada
dc.contributor.authoraffiliation[Cobo Dols, M.] Hosp Univ Reg & Virgen Victoria, Unidad Gest Clin Intercentros Oncol Med, Med Oncol, IBIMA, Malaga, Spain
dc.contributor.authoraffiliation[Andric, Z.] Univ Hosp Med Ctr Bezanijska Kosa, Med Oncol, Belgrade, Serbia
dc.contributor.authoraffiliation[Barrios, C. H.] Pontificia Univ Catolica Rio Grande do Sul, Oncol Res Ctr HSL, Internal Med, Porto Alegre, RS, Brazil
dc.contributor.authoraffiliation[Yamaguchi, M.] Kyushu Canc Ctr, Natl Hosp Org, Dept Thorac Oncol, Otsu, Shiga, Japan
dc.contributor.authoraffiliation[Dansin, E.] Ctr Oscar Lambret, Med Oncol, Lille, France
dc.contributor.authoraffiliation[Danchaivijitr, P.] Siriraj Hosp, Dept Med, Fac Med, Bangkok, Thailand
dc.contributor.authoraffiliation[Johnson, M.] Sarah Cannon Res Inst, Lung, Nashville, TN USA
dc.contributor.authoraffiliation[Novello, S.] Univ Turin, S Luigi Gonzaga Hosp, Oncol, Orbassano, Italy
dc.contributor.authoraffiliation[Gandara, D. R.] Univ Calif Davis, Ctr Comprehens Canc, Internal Med & Hematol Oncol, Sacramento, CA USA
dc.contributor.authoraffiliation[Wang, J.] Genentech Inc, Biostatist, San Francisco, CA USA
dc.contributor.authoraffiliation[Mok, T. S. K.] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China
dc.contributor.funderF. Hoffmann-La Roche, Ltd.
dc.date.accessioned2025-01-07T15:15:44Z
dc.date.available2025-01-07T15:15:44Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1883
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1883
dc.identifier.urihttps://hdl.handle.net/10668/26996
dc.identifier.wosID700527702210
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen de la Victoria
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.organizationInstituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)
dc.page.numberS950-S951
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleAtezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Virgen de la Victoria
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
Instituto de Investigación Biomédica de Málaga - Plataforma Bionand (IBIMA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía